(25R)-5α-Spirostan-2α,3β,5α,6α-tetraol | 137304-85-9

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: (25R)-5α-Spirostan-2α,3β,5α,6α-tetraol
• 英文别名: (1S,2S,4S,5'R,6R,7S,8R,9S,12S,13R,15R,16R,18R,19S)-5',7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icosane-6,2'-oxane]-15,16,18,19-tetrol
• CAS: 137304-85-9
• 化学式: C₂₇H₄₄O₆
• 分子量: 464.643
• InChiKey: JASYOPOIUHUBJK-UKQBOHDZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  33
• 可旋转键数：
  0
• 环数：
  6.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  99.4
• 氢给体数：
  4
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  (25R)-5α-Spirostan-2α,3β,5α,6α-tetraol 、 2,2-二甲氧基丙烷 在 对甲苯磺酸 作用下， 反应 4.0h， 以5.9 mg的产率得到(3aR,4aR,5'R,7aR,8aR,8bS,10aS,10bR,11S,12R,13aS,14aS,14bS,15aS)-2,2,5',6,6,8a,10a,11-octamethylicosahydro-4H-spiro[furo[2'',3'':4',5']cyclopenta[1',2':7,8]phenanthro[2,3-d:10,10a-d']bis([1,3]dioxole)-12,2'-pyran]
  参考文献：
  名称：

  Steroidal saponins from Allium giganteum and A. aflatunense

  摘要：

  Chemical examination of the bulbs of Allium giganteum and A. aflatunense has led to the isolation of two new steroidal saponins together with a known saponin. The structure of the new saponin from A. giganteum was characterized as (24S,25R)-5-alpha-spirostan-2-alpha,3-beta,5-alpha,6-beta,24-pentaol 24-O-beta-D-glucopyranoside and that from A. aflatunense as (25R)-5-aplha-spirostan-2-alpha,3-beta,5-alpha,6-alpha-tetraol 2-O-beta-D-glucopyranoside by spectral and chemical means, and by comparing the data with those of a known compound.

  DOI：

  10.1016/s0031-9422(00)98253-0

文献信息

• Use of core 2 GlcNac-T inhibitors III for treating autoimmune diseases
  申请人：BTG International Limited

  公开号：EP2382979A2

  公开（公告）日：2011-11-02

  Treatments for conditions involving detrimental activity of the enzyme core 2 GlcNAc - T are provided using compounds of the formula I wherein R1 is H, -OH, C1-6 alkoxy, -NR5R6, or Sac 1; R2 is H, -OH, C1-6 alkoxy or Sac 2; R3 is H, -OH, C1-6 alkoxy or Sac 3; R4 is H, C1-6 alkyl, C1-6 hydroxyalkyl or C1-6-alkoxy-C1-6-alkyl; R5 is H, C1-6 alkyl or C1-6 acyl; R6 is H, C1-6 alkyl or C1-6 acyl; Sac 1 Sac 2 and Sac 3 are independently selected saccharide moieties; and Z is a steroid moiety; or a pharmaceutically acceptable salt, ether or ester form thereof, wherein the condition is an autoimmune condition.

  使用式 I 的化合物可治疗涉及核心 2 GlcNAc - T 酶有害活性的病症。 其中 R1 是 H、-OH、C1-6 烷氧基、-NR5R6 或 Sac 1； R2 是 H、-OH、C1-6 烷氧基或 Sac 2； R3 是 H、-OH、C1-6 烷氧基或 Sac 3； R4 是 H、C1-6-烷基、C1-6-羟基烷基或 C1-6- 烷氧基-C1-6-烷基； R5 是 H、C1-6 烷基或 C1-6酰基； R6 是 H、C1-6 烷基或 C1-6 丙烯酸基； Sac 1 Sac 2 和 Sac 3 是独立选定的糖分子；以及 Z 是类固醇分子； 或其药学上可接受的盐、醚或酯形式，其中所述病症为自身免疫性病症。
• Use of Core 2 GlcNac-T inhibitors III for treating vascular complications of diabetes
  申请人：BTG International Limited

  公开号：EP2382980A2

  公开（公告）日：2011-11-02

  Treatments for conditions involving detrimental activity of the enzyme core 2 GlcNAc - T are provided using compounds of the formula I wherein R1 is H, -OH, C1-6 alkoxy, -NR5R6, or Sac 1; R2 is H, -OH, C1-6 alkoxy or Sac 2; R3 is H, -OH, C1-6 alkoxy or Sac 3; R4 is H, C1-6 alkyl, C1-6 hydroxyalkyl or C1-6-alkoxy-C1-6-alkyl; R5 is H, C1-6 alkyl or C1-6 acyl; R6 is H, C1-6 alkyl or C1-6 acyl; Sac 1 Sac 2 and Sac 3 are independently selected saccharide moieties; and Z is a steroid moiety; or a pharmaceutically acceptable salt, ether or ester form thereof, wherein the condition is selected from vascular complications of diabetes.

  使用式 I 的化合物可治疗涉及核心 2 GlcNAc - T 酶有害活性的病症。 其中 R1 是 H、-OH、C1-6 烷氧基、-NR5R6 或 Sac 1； R2 是 H、-OH、C1-6 烷氧基或 Sac 2； R3 是 H、-OH、C1-6 烷氧基或 Sac 3； R4 是 H、C1-6-烷基、C1-6-羟基烷基或 C1-6- 烷氧基-C1-6-烷基； R5 是 H、C1-6 烷基或 C1-6酰基； R6 是 H、C1-6 烷基或 C1-6 丙烯酸基； Sac 1 Sac 2 和 Sac 3 是独立选定的糖分子；以及 Z 是类固醇分子； 或其药学上可接受的盐、醚或酯形式，其中所述病症选自糖尿病的血管并发症。
• Use of Core 2 GlcNac-T inhibitors III for the treatment of inflammatory conditions
  申请人：BTG International Limited

  公开号：EP2382981A2

  公开（公告）日：2011-11-02

  Treatments for conditions involving detrimental activity of the enzyme core 2 GlcNAc - T are provided using compounds of the formula I wherein R1 is H, -OH, C1-6 alkoxy, -NR5R6, or Sac 1; R2 is H, -OH, C1-6 alkoxy or Sac 2; R3 is H, -OH, C1-6 alkoxy or Sac 3; R4 is H, C1-6 alkyl, C1-6 hydroxyalkyl or C1-6-alkoxy-C1-6-alkyl; R5 is H, C1-6 alkyl or C1-6 acyl; R6 is H, C1-6 alkyl or C1-6 acyl; Sac 1 Sac 2 and Sac 3 are independently selected saccharide moieties; and Z is a steroid moiety; or a pharmaceutically acceptable salt, ether or ester form thereof, wherein the condition to be treated is an inflammatory condition selected from ileitis, cholitis, cholecystitis, diverticulitis, gastritis, irritable bowel syndrome, inflammatory bowel disease, Lupus and ulcerative cholitis.

  使用式 I 的化合物可治疗涉及核心 2 GlcNAc - T 酶有害活性的病症。 其中 R1 是 H、-OH、C1-6 烷氧基、-NR5R6 或 Sac 1； R2 是 H、-OH、C1-6 烷氧基或 Sac 2； R3 是 H、-OH、C1-6 烷氧基或 Sac 3； R4 是 H、C1-6-烷基、C1-6-羟基烷基或 C1-6- 烷氧基-C1-6-烷基； R5 是 H、C1-6 烷基或 C1-6酰基； R6 是 H、C1-6 烷基或 C1-6 丙烯酸基； Sac 1 Sac 2 和 Sac 3 是独立选择的糖分子；以及 Z 是类固醇分子； 或其药学上可接受的盐、醚或酯形式，其中待治疗的病症是选自回肠炎、胆囊炎、胆囊炎、憩室炎、胃炎、肠易激综合征、炎症性肠病、红斑狼疮和溃疡性胆炎的炎症。
• STEROIDAL GLYCOSIDE COMPOUNDS AS CORE 2 GLCNAC-T INHIBITORS
  申请人：BTG International Limited

  公开号：EP1909802A2

  公开（公告）日：2008-04-16
• Steroidal glycoside compounds as core 2 GlcNAc-T inhibitors
  申请人：BTG International Limited

  公开号：EP1909802B1

  公开（公告）日：2014-05-21